The definitive directory of gene and cell therapy developers, spanning CAR-T and engineered immune cell therapy, CRISPR and next-generation gene editing, AAV gene therapy, rare disease programs, in vivo delivery platforms, and cell & gene manufacturing. Curated for biotech investors, business development leads, and scientists tracking the CGT landscape.
BioMed Nexus tracks 170 gene and cell therapy companies across 7 categories: CAR-T & immune cell therapy, gene editing & CRISPR, AAV gene therapy, rare disease, in vivo delivery, platform & tools, and autoimmune & other cell therapies. The directory covers the leading CGT developers, including CRISPR Therapeutics, Intellia, Beam, Sarepta, Kite Pharma and Legend Biotech, alongside emerging biotechs. Last updated July 2026
Priority placement at the top of the directory, a dedicated landing page, and a featured newsletter segment reaching 65,000+ subscribers. Limited spots available.
Right now, every company in this directory is just a name in a database. Featured partners get a full profile with logo, pipeline, modality, backlinks, and priority placement at the very top of this page, seen by 65,000+ biotech professionals every week. Claim the top spot before your competitors do.
The BioMed Nexus Gene & Cell Therapy Companies Directory is a comprehensive, regularly updated list of gene and cell therapy developers, spanning CAR-T and engineered immune cell therapy, CRISPR and next-generation gene editing, AAV gene therapy, ex vivo rare disease therapies, in vivo delivery platforms, cell and gene therapy manufacturing (CDMO) and tools, and emerging autoimmune cell therapies. It covers approved-therapy leaders alongside clinical- and preclinical-stage biotechs.
Use it to research gene and cell therapy companies by modality, track the competitive landscape, and map CDMO and platform partners. Whether you are a biotech investor evaluating the CGT sector, a business development lead scouting partners, or a scientist tracking modalities, the directory provides structured, current company data. Curated and maintained by the BioMed Nexus editorial team; last updated July 2026.
Companies can claim a free basic listing or become a Featured Partner for priority placement, a dedicated landing page, backlinks, and a featured segment in the BioMed Nexus daily newsletter reaching 65,000+ subscribers. Contact our partnerships team to learn more.
